drug-interaction-995x60.png drug-interaction-995x60.png

FEATURED ARTICLES

ASCO To Take A Closer Look At Patient-Reported Outcomes In Clinical Trials And Cancer Care
ASCO To Take A Closer Look At Patient-Reported Outcomes In Clinical Trials And Cancer Care

While the annual meetings of the American Society of Clinical Oncology (ASCO) can almost always be counted on to generate news about scientific breakthroughs in understanding and treating cancer, the theme for this year’s conference goes beyond that conventional approach. ASCO 2016 Annual Meeting will prominently feature discussions about how clinicians can best integrate recent advances, and particularly how to best assess the impact on real-world patients.

  • Bringing A Billion-Dollar Drug To Market

    A report by Deloitte on the world’s 12 largest drugmakers shows that the average cost of bringing a product to market rose by more than 25% to greater than $1B in 2011, from $830M in 2010. By Cindy Dubin

  • Gaining Greater Predictability, Control And Quality In Bioprocessing With Metabolic Biomarkers
    Gaining Greater Predictability, Control And Quality In Bioprocessing With Metabolic Biomarkers

    Biologics are an integral part of the landscape of current therapies as pipelines continue to fill with them. Due to their importance and this ever expanding pipeline, the demands continue to escalate due to cost pressure, competition, regulatory requirements, disposable systems, and biosimilars. To date, these demands arguably have primarily been met with empirical understanding. However, there is a critical need for new approaches, tools, and technologies to deliver deeper understanding beyond the empirical realm. By Dr. Kirk Beebe, Director of Application Science, Metabolon, Inc.

More Featured Articles

WHITE PAPERS AND CASE STUDIES

  • Considerations When Selecting A CRO For Phase I Clinical Studies

    Phase I clinical trials are an integral step in the drug development process. Specific factors can influence the timelines and success of these studies. This white paper addresses the critical success factors for Phase I clinical studies and provides guidance on the appropriate capabilities, expertise and experience to evaluate as a sponsor selects a CRO.

  • Streamline And Accelerate A Drug Development Plan Using The 505(b)(2) Pathway

    An international pharmaceutical company approached Camargo Pharmaceutical Services to help navigate the Food and Drug Administration (FDA) 505(b)(2) approval pathway for a promising drug under development designated for patients with cardiovascular disease. Product X is a prodrug that is converted in one metabolism-dependent step to produce the active metabolite of an approved drug.

  • ICON Clinical Development Overview

    ICON is one of the world’s largest providers of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.

  • Drug Safety: Providing Strategies And Solutions To Help Sponsors

    At ICON, we have the expertise that spans the entire lifecycle of drug development. Our team of global safety experts is ideally positioned to design and implement comprehensive drug risk management programs and Phase IV safety surveillance programs.

  • Clinical Pharmacology Datasheet

    The clinical pharmacology team at ICON Development Solutions (ICON) has extensive experience in the design, study conduct and interpretation of clinical pharmacology studies across all major therapeutic areas.

  • Early Phase Development Datasheet

    ICON Development Solutions specializes in the strategy and delivery of early phase clinical development for informed, timely decision making. With expertise in early phase clinical research, bioanalytical, PK/PD modelling & simulation and the full range of supporting services, we incorporate scientific excellence and product development strategy in all that we do.

More White Papers & Case Studies

SERVICES AND PRODUCTS

Bioanalytical Laboratories Bioanalytical Laboratories

With over 1,500 assays developed in support of over 2,500 studies and with management experience averaging 21 years, ICON Development Solutions has the bioanalytical expertise and track record required to deliver rapid, dependable results. 

Clinical Pharmacology Clinical Pharmacology

The clinical pharmacology team at ICON Development Solutions (ICON) has extensive experience in the design, study conduct and interpretation of clinical pharmacology studies across all major therapeutic areas.

Bioanalytical Services Bioanalytical Services

For over 20 years, the bioanalytical services group of ICON Development Solutions has provided analytical testing services to meet the research and development challenges of the pharmaceutical and biotechnology industries.

Early Phase Early Phase

ICON Development Solutions specialises in the strategy and delivery of early-phase clinical development services to enable informed, timely decision making for our clients.

Clinic Profiles Clinic Profiles
You want to provide a safe environment and a rewarding experience for healthy volunteers during clinical trials. Quintiles delivers that atmosphere, drawing on more than 25 years' experience handling Phase I clinical research and clinical trial monitoring.
More Services & Products

NEWS

More News

ABOUT